ADAPTING THE RANDOMIZATION ALGORITHM

Discover how IDDI biostatistics-driven RTSM helped the Sponsor to avoid serious imbalance between the two randomized arms for the treated patients

SITUATION:

  • A randomized Phase III trial to evaluate the efficacy and safety of a new drug to treat critical limb ischemia
  • A randomized phase 3 study using a 2:1 minimization algorithm (with 0.8 as the probability) balancing the patients according to minimization factors between 2 arms (Active and Placebo)

CHALLENGES

  • The treatment is only manufactured if the patient is randomized to Active arm. Treatment is using the bone marrow of the patient.
  • If the product cannot be manufactured or is damaged during the transportation, the randomized patient will not be treated.
    => This caused serious imbalance between the two randomized arms for the treated patient

PLEASE FILL IN THE FORM TO ACCESS THE CASE STUDY  

RANDOMIZATION ALGORITHM

    By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

    I authorize IDDI to use my data to contact me for commercial purposes.More information